Cargando…
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
BACKGROUND: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly (ie, once eve...
Autores principales: | Clamp, Andrew R, James, Elizabeth C, McNeish, Iain A, Dean, Andrew, Kim, Jae-Won, O'Donnell, Dearbhaile M, Gallardo-Rincon, Dolores, Blagden, Sarah, Brenton, James, Perren, Tim J, Sundar, Sudha, Lord, Rosemary, Dark, Graham, Hall, Marcia, Banerjee, Susana, Glasspool, Rosalind M, Hanna, C Louise, Williams, Sarah, Scatchard, Kate M, Nam, Helena, Essapen, Sharadah, Parkinson, Christine, McAvan, Lucy, Swart, Ann Marie, Popoola, Babasola, Schiavone, Francesca, Badrock, Jonathan, Fananapazir, Fuad, Cook, Adrian D, Parmar, Mahesh, Kaplan, Richard, Ledermann, Jonathan A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lancet Pub. Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630160/ https://www.ncbi.nlm.nih.gov/pubmed/35690073 http://dx.doi.org/10.1016/S1470-2045(22)00283-2 |
Ejemplares similares
-
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
por: Clamp, Andrew R, et al.
Publicado: (2019) -
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
por: Blagden, Sarah P, et al.
Publicado: (2020) -
Impact of retrospective data verification to prepare the ICON6 trial
for use in a marketing authorization application
por: Embleton-Thirsk, Andrew, et al.
Publicado: (2019) -
Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013) -
Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
por: Tong, Daniel, et al.
Publicado: (2021)